Description: Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Home Page: www.prothena.com
77 Sir John Rogerson’s Quay
Dublin,
D02 VK60
Ireland
Phone:
353 1 236 2500
Officers
| Name | Title |
|---|---|
| Dr. Gene G. Kinney Ph.D. | President, CEO & Director |
| Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer |
| Mr. Brandon S. Smith | Chief Operating Officer |
| Ms. Carol D. Karp | Chief Regulatory Officer |
| Ms. Karin L. Walker CPA | Chief Accounting Officer & Controller |
| Dr. Wagner M. Zago Ph.D. | Chief Scientific Officer |
| Mr. Mark C. Johnson C.F.A. | Vice President of Investor Relations |
| Mr. Michael J. Malecek | Chief Legal Officer |
| Mr. David A. Ford | Chief People Officer |
| Dr. Chad J. Swanson Ph.D. | Chief Development Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 65.7895 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.3857 |
| Price-to-Sales TTM: | 5.3472 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 173 |